Endpoints News 生物医药· ENDPOINTS·· 16 天前AI 评分33
Spyre 疗法的抗 TL1A 药物 SPY072 临床试验失败
Spyre’s arthritis misses; Ideaya ends eye cancer trial
AI 导读
Spyre Therapeutics 报告其长效抗 TL1A 药物 SPY072 临床试验失败。该试验旨在治疗自身免疫性疾病。
正文
Plus news about United Therapeutics.
Spyre Therapeutics reports additional trial failures: The biotech said its long-acting anti-TL1A drug, codenamed SPY072, did …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news